Background: Currently, studies have shown that anti-CGRP monoclonal antibodies are effective drugs for the prophylaxis and treatment of episodic migraine. Therefore, for the first time, we classified and concluded 10 treatment regimens according to the different doses, drugs, routes of administration, and courses of treatment, so as to provide a reference for further clinical studies.
Methods: We studied relevant randomized controlled trials (RCTs) published before August 2020 on PubMed, Embase, Ovid MEDLINE, Web of Science, and the Cochrane Central Register of Controlled Trials.
Results: Eleven RCTs involving 6397 patients were included in our analysis. Network meta-analysis results suggested that in the comparison of the average migraine days per month, Erenumab (140 mg), Galcanezumab (120 mg, 240 mg), Fremanezumab (225 mg, 675 mg) were superior to placebo, Erenumab(7 mg), and the difference was statistically significant; Fremanezumab (225 mg, 675 mg) was superior to Erenumab (21 mg, 70 mg), and the difference was statistically significant; in the comparison of average medication days of acute migraine-specific drug per month, Erenumab (70 mg, 140 mg), Galcanezumab (120 mg, 240 mg), Fremanezumab (225 mg, 675 mg) was superior to placebo, and Erenumab (140 mg) and Galcanezumab (120 mg, 240 mg) were superior to Erenumab (70 mg), and the difference was statistically significant; there was no statistically significant difference in the average migraine days in the last month or in the medication days of acute migraine-specific drug.
Conclusion: Fremanezumab (225 mg) and Galcanezumab (120 mg) may be the best clinical protocol after a comprehensive assessment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/01616412.2021.1940672 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of galcanezumab for cluster headache preventive treatment: a systematic review and meta-analysis.
Neurol Res
January 2025
Neurology, Division of General Neurology and Headache, University of Rochester, Rochester, NY, USA.
Article Synopsis
- Galcanezumab is a monoclonal antibody that targets the CGRP pathway, representing a new treatment option for cluster headaches (CH).
- A systematic review and meta-analysis of six studies, involving 504 patients, evaluated the drug's effectiveness and safety, finding a significant reduction in CH attack frequency in 76% of participants.
- While 48% of patients experienced treatment-emergent adverse events, the side effects were notably higher in those taking the 300 mg dose compared to the 240 mg dose, suggesting galcanezumab is generally effective and safe for managing CH.
Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody Is Effective for Preventing Migraine Aura Without Headache.
Neurol Int
October 2024
Department of Neurosurgery, Headache Clinic, Mito Medical Center, University of Tsukuba, Ibaraki 310-0015, Japan.
Background: Anti-calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) are clinically effective in preventing the migraine attacks, photophobia, and migraine auras associated with headaches. However, no study has yet investigated the effectiveness of CGRP mAbs in preventing migraine aura without headache.
Case Report: A female patient of 49 years old presented with a long history (since age 10) of photosensitivity and typical migraine auras without a headache.
Galcanezumab add-on in refractory cluster headache. A case series.
Pain Manag
September 2024
First Department of Neurology, Aeginitio Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Cluster headache (CH), a highly disabling condition, lacks disease-specific, mechanism-based prophylactic treatment. Galganezumab, a monoclonal antibody targeting the calcitonin gene-related peptide, reduced the weekly attacks of CH in one randomized, placebo-controlled trial for the prevention of episodic CH (eCH), but this effect was not detected in people with chronic CH (cCH). In this case series, we systematically monitored the efficacy and safety outcomes of adjunctive therapy in 11 people with refractory CH (failure of ≥ 3 prophylactic treatments; eCH = 5, cCH, = 6) who received galcanezumab (120-360 mg monthly) for 3 consecutive months.
View Article and Find Full Text PDFA placebo controlled, randomized clinical trial of galcanezumab for vestibular migraine: The INVESTMENT study.
Headache
November 2024
Department of Neurology, University of California, San Francisco, San Francisco, California, USA.
Objective: To study if galcanezumab is effective for vestibular migraine (VM).
Background: There are currently no placebo-controlled trials showing that treatment is effective for VM. Therefore, we performed the first placebo controlled, randomized clinical trial of a calcitonin gene-related peptide-targeted monoclonal antibody for VM.
Anti‑CGRP monoclonal antibodies in resistant migraine: preliminary real-world effectiveness and clinical predictors of response at two years.
Int J Clin Pharm
December 2024
Clinical Pharmacy and Therapeutics Research Group, Servicio de Farmacia Hospitalaria, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Biomedical Research Institute of Murcia (IMIB), Ctra. Madrid-Cartagena, s/n, 30120, El Palmar, Murcia, Spain.
Background: Monoclonal antibodies targeting calcitonin gene-related peptide (anti-CGRP mAbs) have shown clinical effectiveness and safety in randomized clinical studies. However, long-term studies in clinical practice remain limited.
Aim: To assess the long-term effectiveness, clinical predictors and safety of three anti-CGRP mAbs (erenumab, galcanezumab, fremanezumab) in resistant migraine patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!